Bioxyne Ltd - Company Profile
Powered by 
All the sales intelligence you need on Bioxyne Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Bioxyne Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Bioxyne Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Bioxyne Ltd (Bioxyne) is a life sciences company. It manufactures and distributes consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative novel medicines. Bioxyne focuses on the pharmaceutical manufacturing and wholesale supply of novel medicines, medicinal cannabis, psilocybin, and 4-Methylenedioxymethamphetamine (MDMA) through BLS Wholesalers Pty Limited; the manufacture and distribution of consumer health products, including cannabidiol and functional mushrooms under the Dr Watson brand across the UK, Europe, and Japan; and the wholesale distribution of patented probiotics for gastrointestinal health and immunity, primarily to the US. The company has manufacturing and distribution centers in Australia, Japan, the UK, and Europe. Bioxyne is headquartered in Sydney, New South Wales, Australia.
Bioxyne Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Novel Medicines | Dr Watson |
| Medicinal Cannabis | Breathe Life Sciences |
| Psilocybin | BLS Clinics |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In December, the company's subsidiary, Breathe Life Sciences (BLS), entered into a manufacturing and supply agreement with Remidose LATAM SRL, to facilitate Bioxyne's entry into the medicinal cannabis markets of Costa Rica and Panama. |
| 2024 | New Products/Services | In August, the company manufactured and delivered Australia’s first pharmaceutical cannabis pastilles (Gummies or Edibles). |
| 2024 | Contracts/Agreements | In May, the company entered into a commercial supply and collaboration agreement with Cy Biopharma AG of Switzerland. |
Competitor Comparison
| Key Parameters | Bioxyne Ltd | Probiotec Ltd | BLIS Technologies Ltd | Amplia Therapeutics Ltd | BioCeuticals Pty Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Australia | New Zealand | Australia | Australia |
| City | Sydney | Melbourne | Dunedin | Melbourne | Surry Hills |
| State/Province | New South Wales | Victoria | Otago | Victoria | New South Wales |
| No. of Employees | 16 | 111 | 39 | 1 | - |
| Entity Type | Public | Private | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Samuel Watson | Chief Executive Officer; Managing Director | Executive Board | 2023 | - |
| Jason Hine | Chief Operating Officer; Director | Executive Board | 2023 | - |
| Guy Robertson | Chief Financial Officer; Secretary | Senior Management | 2016 | - |
| Anthony Ho | Chairman | Non Executive Board | 2012 | - |
| Macdarragh O'Neill | Head - Production (GMP); Director - BLS Wholesalers Pty | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer